Osteoporosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of osteoporosis (OSP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OSP for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s OSP forecast answers the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OSP over the forecast period?
  • How will changes in the levels of exposure to known risk or protective factors affect the number of people at high risk for hip fracture (HF) or a major osteoporotic fracture (MOF)?
  • Of all people with OSP, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with OSP, how many in each of the major mature pharmaceutical markets are drug-treated?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts seven OSP patient populations, as follows:

  • Total prevalent cases by the World Health Organization (WHO) definition.
  • Total prevalent cases by the National Bone Health Alliance (NBHA) definition.
  • Total Fracture Risk Assessment (FRAX) high-risk prevalent cases.
  • Diagnosed prevalent cases.
  • Undiagnosed prevalent cases.
  • Diagnosed drug-treated prevalent cases.
  • Diagnosed non-drug-treated prevalent cases.

Note: Coverage may vary by country.